Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, S.T. | - |
dc.contributor.author | Lim, D.H. | - |
dc.contributor.author | Jang, K.-T. | - |
dc.contributor.author | Lim, T. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Choi, Y.-L. | - |
dc.contributor.author | Jang, H.-L. | - |
dc.contributor.author | Yi, J.H. | - |
dc.contributor.author | Baek, K.K. | - |
dc.contributor.author | Park, S.H. | - |
dc.contributor.author | Park, Y.S. | - |
dc.contributor.author | Lim, H.Y. | - |
dc.contributor.author | Kang, W.K. | - |
dc.contributor.author | Park, J.O. | - |
dc.date.accessioned | 2021-09-07T20:20:09Z | - |
dc.date.available | 2021-09-07T20:20:09Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 1535-7163 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/114605 | - |
dc.description.abstract | Although erlotinib has become an important therapeutic option in addition to gemcitabine, the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We retrospectively studied 136 pancreatic cancer patients with available formalin-fixed paraffin-embedded tumor blocks from 2003 to 2009 to understand the clinical significance of KRAS mutations in pancreatic cancer patients treated with gemcitabine-based chemotherapy. KRAS mutations were analyzed by sequencing codons 12, 13, and 61. In this study, 71 (52.2%) of the 136 pancreatic adenocarcinomas examined harbored a point mutation in codons 12 (n=70) and 61 (n=1) of KRAS. KRAS mutation was not associated with clinicopathologic parameters. Patients with KRAS mutations showed a worse response (11.3%) than those with wild-type KRAS (26.2%) and poor survival (mutant KRAS, 5.8 months vs. wild-type KRAS, 8.0 months; P = 0.001). Multivariate analysis revealed good prognostic factors for overall survival as well to moderately differentiated histology (P < 0.001; HR =0.437, 95% CI: 0.301-0.634), locally advanced disease (P < 0.001; HR = 0.417, 95% CI: 0.255-0.681), response to first-line chemotherapy (P = 0.003; HR = 0.482, 95% CI: 0.297-0.780), and wild-type KRAS (P = 0.001; HR = 0.523, 95% CI: 0.355-0.770). However, the observed survival advantage is derived from the subgroup of patients treated with gemcitabine/erlotinib (9.7 vs. 5.2 months; P = 0.002), whereas no survival difference based on KRAS mutation status is obvious in the other subgroup of patients treated without erlotinib (7.0 vs. 7.0 months; P = 0.121). These results need to be further explored in upcoming prospective studies to provide a rationale for personalized medicine in pancreatic cancer. ©2011 AACR. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | capecitabine | - |
dc.subject | erlotinib | - |
dc.subject | gemcitabine | - |
dc.subject | K ras protein | - |
dc.subject | UFT | - |
dc.subject | adult | - |
dc.subject | aged | - |
dc.subject | article | - |
dc.subject | cancer chemotherapy | - |
dc.subject | cancer patient | - |
dc.subject | cancer survival | - |
dc.subject | codon | - |
dc.subject | controlled study | - |
dc.subject | female | - |
dc.subject | gene mutation | - |
dc.subject | gene sequence | - |
dc.subject | histology | - |
dc.subject | human | - |
dc.subject | human tissue | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | multivariate analysis | - |
dc.subject | outcome assessment | - |
dc.subject | overall survival | - |
dc.subject | pancreas adenocarcinoma | - |
dc.subject | pancreas cancer | - |
dc.subject | point mutation | - |
dc.subject | priority journal | - |
dc.subject | retrospective study | - |
dc.subject | treatment response | - |
dc.subject | wild type | - |
dc.subject | Aged | - |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject | Carcinoma, Pancreatic Ductal | - |
dc.subject | Deoxycytidine | - |
dc.subject | Female | - |
dc.subject | Genes, ras | - |
dc.subject | Humans | - |
dc.subject | Middle Aged | - |
dc.subject | Mutation | - |
dc.subject | Pancreatic Neoplasms | - |
dc.subject | Quinazolines | - |
dc.subject | Treatment Outcome | - |
dc.title | Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, S.T. | - |
dc.identifier.doi | 10.1158/1535-7163.MCT-11-0269 | - |
dc.identifier.scopusid | 2-s2.0-80054000816 | - |
dc.identifier.bibliographicCitation | Molecular Cancer Therapeutics, v.10, no.10, pp.1993 - 1999 | - |
dc.relation.isPartOf | Molecular Cancer Therapeutics | - |
dc.citation.title | Molecular Cancer Therapeutics | - |
dc.citation.volume | 10 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1993 | - |
dc.citation.endPage | 1999 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | capecitabine | - |
dc.subject.keywordPlus | erlotinib | - |
dc.subject.keywordPlus | gemcitabine | - |
dc.subject.keywordPlus | K ras protein | - |
dc.subject.keywordPlus | UFT | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | cancer chemotherapy | - |
dc.subject.keywordPlus | cancer patient | - |
dc.subject.keywordPlus | cancer survival | - |
dc.subject.keywordPlus | codon | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | gene mutation | - |
dc.subject.keywordPlus | gene sequence | - |
dc.subject.keywordPlus | histology | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | human tissue | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | multivariate analysis | - |
dc.subject.keywordPlus | outcome assessment | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | pancreas adenocarcinoma | - |
dc.subject.keywordPlus | pancreas cancer | - |
dc.subject.keywordPlus | point mutation | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | treatment response | - |
dc.subject.keywordPlus | wild type | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Antineoplastic Combined Chemotherapy Protocols | - |
dc.subject.keywordPlus | Carcinoma, Pancreatic Ductal | - |
dc.subject.keywordPlus | Deoxycytidine | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Genes, ras | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Mutation | - |
dc.subject.keywordPlus | Pancreatic Neoplasms | - |
dc.subject.keywordPlus | Quinazolines | - |
dc.subject.keywordPlus | Treatment Outcome | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.